Loading
A phase 2 trial of irinotecan (and liposomal irinotecan), fluorouracil (5-FU), leucovorin (folinic acid) and bevacizumab (glioblastoma use) in colorectal cancer, run by Hebei Medical University Fourth Hospital, now recruiting.
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06184698 by Hebei Medical University Fourth Hospital, with a registry enrolment figure of 173 participants, started 2024-01-01 and due to reach its primary completion in 2026-02-01. Interventions recorded: liposomal irinotecan; 5-FU; LV; Bevacizumab. Conditions listed: Colorectal Cancer. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: "* Histologically or cytologically proven colon or rectum adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), Leucovorin (folinic acid), Fluorouracil (5-FU) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Leucovorin (folinic acid), Fluorouracil (5-FU), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Leucovorin (folinic acid), Fluorouracil (5-FU), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), Leucovorin (folinic acid), Fluorouracil (5-FU) and the tag colorectal-deep-dive.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), Leucovorin (folinic acid), Fluorouracil (5-FU) and the tag colorectal-deep-dive.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Fluorouracil (5-FU), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.